Skip to main content
Top
Published in: Rheumatology International 1/2012

01-01-2012 | Original Article

Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus

Authors: Mehmet Sayarlioglu, Nergis Yuzbasioglu, Murat Inanc, Sevil Kamali, Ayse Cefle, Ozcan Karaman, Ahmet Mesut Onat, Rustem Avan, Gozde Yildirm Cetin, Ahmet Gul, Lale Ocal, Orhan Aral

Published in: Rheumatology International | Issue 1/2012

Login to get access

Abstract

The objective was to investigate the predictive factors for avascular necrosis (AVN) of bone in patients with systemic lupus erythematosus (SLE). The records of 868 patients with SLE from four centers were reviewed retrospectively. Forty-nine patients with AVN were identified. A total of 154 patients with SLE who did not have clinically apparent AVN during the follow-up were evaluated as a control group. The demographic, clinical, laboratory and management characteristics of these two groups of patients were recorded according to predefined protocol and compared. The prevalence of AVN was detected 6% in our SLE population. The highest dose corticosteroid administered within 4 months and total cumulative prednisolone dose were significantly higher in the SLE patients with AVN. The use of cytotoxic agent significantly higher proportion of patients with AVN. AVN tends to develop more frequently in male gender and younger patients. Oral ulcer, pleuritis, Raynaud’s phenomenon, cutaneous vasculitis, lymphadenopathy, autoimmune thyroiditis, peripheral neuropathy and Sjögren’s syndrome were higher incidence in SLE patients with AVN. The bilateral femoral heads were the commonest site of involvement of AVN in our patients with SLE.
Literature
1.
go back to reference Abu-Shakra M, Buskila D, Shoenfeld Y (2003) Osteonecrosis in patients with SLE. Clin Rev Allergy Immunol 25:13–24PubMedCrossRef Abu-Shakra M, Buskila D, Shoenfeld Y (2003) Osteonecrosis in patients with SLE. Clin Rev Allergy Immunol 25:13–24PubMedCrossRef
2.
go back to reference Petri M (1995) Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. Arthritis Care Res 8:137–145PubMedCrossRef Petri M (1995) Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. Arthritis Care Res 8:137–145PubMedCrossRef
3.
go back to reference Gladman DD, Chaudhry-Ahluwalia V, Ibañez D, Bogoch E, Urowitz MB (2001) Outcomes of symptomatic osteonecrosis in 95 patients with systemic lupus erythematosus. J Rheumatol 28:2226–2229PubMed Gladman DD, Chaudhry-Ahluwalia V, Ibañez D, Bogoch E, Urowitz MB (2001) Outcomes of symptomatic osteonecrosis in 95 patients with systemic lupus erythematosus. J Rheumatol 28:2226–2229PubMed
4.
go back to reference Dimant J, Ginzler EM, Diamond HS, Schlesinger M, Marino CT, Weiner M, Kaplan D (1978) Computer analysis of factors influencing the appearance of aseptic necrosis in patients with SLE. J Rheumatol 5:136–141PubMed Dimant J, Ginzler EM, Diamond HS, Schlesinger M, Marino CT, Weiner M, Kaplan D (1978) Computer analysis of factors influencing the appearance of aseptic necrosis in patients with SLE. J Rheumatol 5:136–141PubMed
5.
go back to reference Smith FE, Sweet DE, Brunner CM, Davis JS 4th (1976) Avascular necrosis in SLE. An apparent predilection for young patients. Ann Rheum Dis 35:227–232PubMedCrossRef Smith FE, Sweet DE, Brunner CM, Davis JS 4th (1976) Avascular necrosis in SLE. An apparent predilection for young patients. Ann Rheum Dis 35:227–232PubMedCrossRef
6.
go back to reference Zizic TM, Marcoux C, Hungerford DS, Dansereau JV, Stevens MB (1985) Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med 79:596–604PubMedCrossRef Zizic TM, Marcoux C, Hungerford DS, Dansereau JV, Stevens MB (1985) Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med 79:596–604PubMedCrossRef
7.
go back to reference Klipper AR, Stevens MB, Zizic TM, Hungerford DS (1976) Ischemic necrosis of bone in systemic lupus erythematosus. Medicine (Baltimore) 55:251–257CrossRef Klipper AR, Stevens MB, Zizic TM, Hungerford DS (1976) Ischemic necrosis of bone in systemic lupus erythematosus. Medicine (Baltimore) 55:251–257CrossRef
8.
go back to reference Mont MA, Glueck CJ, Pacheco IH, Wang P, Hungerford DS, Petri M (1997) Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 24:654–662PubMed Mont MA, Glueck CJ, Pacheco IH, Wang P, Hungerford DS, Petri M (1997) Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 24:654–662PubMed
9.
go back to reference Gladman DD, Urowitz MB, Chaudhry-Ahluwalia V, Hallet DC, Cook RJ (2001) Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Rheumatol 28:761–765PubMed Gladman DD, Urowitz MB, Chaudhry-Ahluwalia V, Hallet DC, Cook RJ (2001) Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Rheumatol 28:761–765PubMed
10.
go back to reference Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef
11.
go back to reference Nagasawa K, Ishii Y, Mayumi T, Tada Y, Ueda A, Yamauchi Y et al (1989) Avascular necrosis of bone in systemic lupus erythematosus: possible role of haemostatic abnormalities. Ann Rheum Dis 48:672–676PubMedCrossRef Nagasawa K, Ishii Y, Mayumi T, Tada Y, Ueda A, Yamauchi Y et al (1989) Avascular necrosis of bone in systemic lupus erythematosus: possible role of haemostatic abnormalities. Ann Rheum Dis 48:672–676PubMedCrossRef
12.
go back to reference Mok CC, Lau CS, Wong RW (1998) Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol 37:895–900PubMedCrossRef Mok CC, Lau CS, Wong RW (1998) Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol 37:895–900PubMedCrossRef
13.
go back to reference Mok MY, Farewell VT, Isenberg DA (2000) Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies? Ann Rheum Dis 59:462–467PubMedCrossRef Mok MY, Farewell VT, Isenberg DA (2000) Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies? Ann Rheum Dis 59:462–467PubMedCrossRef
14.
go back to reference Leventhal GH, Dorfman HD (1974) Aseptic necrosis of bone in systemic lupus erythematosus. Semin Arthritis Rheum 4:73–93PubMedCrossRef Leventhal GH, Dorfman HD (1974) Aseptic necrosis of bone in systemic lupus erythematosus. Semin Arthritis Rheum 4:73–93PubMedCrossRef
15.
go back to reference Velayos EE, Leidholt JD, Smyth JC, Priest R (1966) Arthropathy associated with steroid therapy. Ann Intern Med 64:759–771 Velayos EE, Leidholt JD, Smyth JC, Priest R (1966) Arthropathy associated with steroid therapy. Ann Intern Med 64:759–771
16.
go back to reference Calvo-Alen J, McGwin G, Toloza S, Fernandez M, Roseman JM, Bastian HM et al (2006) Systemic Lupus Erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study. Ann Rheum Dis 65:785–790PubMedCrossRef Calvo-Alen J, McGwin G, Toloza S, Fernandez M, Roseman JM, Bastian HM et al (2006) Systemic Lupus Erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study. Ann Rheum Dis 65:785–790PubMedCrossRef
17.
go back to reference Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311PubMedCrossRef Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311PubMedCrossRef
18.
go back to reference Asherson RA, Lioté F, Page B, Meyer O, Buchanan N, Khamashta MA et al (1993) Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 20:284–288PubMed Asherson RA, Lioté F, Page B, Meyer O, Buchanan N, Khamashta MA et al (1993) Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 20:284–288PubMed
19.
go back to reference Tektonidou MG, Malagari K, Vlachoyiannopoulos PG, Kelekis DA, Moutsopoulos HM (2003) Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging. Arthritis Rheum 48:732–736PubMedCrossRef Tektonidou MG, Malagari K, Vlachoyiannopoulos PG, Kelekis DA, Moutsopoulos HM (2003) Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging. Arthritis Rheum 48:732–736PubMedCrossRef
Metadata
Title
Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus
Authors
Mehmet Sayarlioglu
Nergis Yuzbasioglu
Murat Inanc
Sevil Kamali
Ayse Cefle
Ozcan Karaman
Ahmet Mesut Onat
Rustem Avan
Gozde Yildirm Cetin
Ahmet Gul
Lale Ocal
Orhan Aral
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 1/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1597-9

Other articles of this Issue 1/2012

Rheumatology International 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.